

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED

銘源醫療發展有限公司*

(incorporated in Bermuda with limited liability)

(Stock Code: 0233)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules.

The Board wishes to inform the shareholders of the Company and potential investors that based on the management's preliminary assessment of the Group's unaudited management accounts, the profitability of the Group in 2011, as compared with 2010, is expected to decrease. The decrease was primarily due to the unsatisfactory performance of the protein chip division of the Group.

Shareholders of the Company and potential investors are advised to exercise caution in dealing in the shares of the Company.

This announcement is made by Mingyuan Medicare Development Company Limited ("the Company", together with its subsidiaries, "the Group") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("the Listing Rules").

The board of directors of the Company (the "Board") wishes to inform the shareholders of the Company and potential investors that based on the management's preliminary assessment of the unaudited management accounts, the profitability of the Group in 2011, as compared with 2010, is expected to decrease. The decrease was primarily due to the unsatisfactory performance of the protein chip division of the Group. The performance of the protein chip division was adversely affected by (i) decrease in sales of protein chip due to overall tightened financing situation in China; and (ii) continuous replacement of old C12 protein chips market by the upgraded C12A protein chips. The replacement is a slow and time consuming exercise and sales of C12A protein chips was delayed during the replacement process.

The Company is still in the process of finalizing the annual results of the Group for year ended 31 December 2011. The information contained in this announcement is only a preliminary assessment of the Board based on the Group's unaudited management accounts which have not yet been audited or reviewed by the Company's auditors. The annual results of the Group for the year ended 31 December 2011 is expected to be finalized and reviewed by the Company's auditors and published before the end of March 2012.

Shareholders of the Company and potential investors are advised to exercise caution in dealing in the shares of the Company.

By order of the Board
Mingyuan Medicare Development Company Limited
銘源醫療發展有限公司*
Kenny Poon
Company Secretary

Hong Kong, 13 February 2012

As at the date of this announcement, the executive directors are Mr. Yao Yuan (Chairman), Mr. Chien Hoe Yong, Henry (CEO), Mr. Hu Jun, and Mr. Yu Ti Jun; the non-executive directors are Mr. Yang Zhen Hua and Mr. Ma Yong Wei; the independent non-executive directors are Dr. Lam Lee G., Mr. Hu Jin Hua, Mr. Lee Sze Ho, Henry and Mr. Tang Yan Qin.

* *For identification purposes only*